alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › era

era

9 studies tagged era, dated 2010-03-05 to 2026-11-04. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Clinical genetics and genetic counseling in the era of disease-modifying therapies for dementia: lessons from Japan 2026-11-04
  2. Organizing healthcare delivery in the era of disease-modifying therapies for Alzheimer's Disease: an Italian RAND/UCLA consensus 2026-10-09
  3. A Cross-Sectional Survey of Knowledge, Confidence, and Decision-Making in Acute Stroke in the Era of Anti-Amyloid Therapies 2026-10-01

Studies

9 studies carry this tag.

Date range

2010 to 2026

Top journals

  • AIDS (London, England) 1
  • Alzheimer's & dementia (Amsterdam, Netherlands) 1
  • Alzheimer's research & therapy 1
  • Cureus 1
  • Free neuropathology 1

9 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Clinical genetics and genetic counseling in the era of disease-modifying therapies for dementia: lessons from Japan

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of human genetics 2026-11-04 Treatments

    Recent advances in hereditary dementia research have clarified its molecular pathogenesis and clinical applications, with several advances already reaching implementation.

  2. Organizing healthcare delivery in the era of disease-modifying therapies for Alzheimer's Disease: an Italian RAND/UCLA consensus

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2026-10-09 Treatments

    This consensus provides a pragmatic framework to support the reorganisation of AD care in Italy, ensuring that every patient is directed to the most appropriate level of care across a flexible regional network.

  3. A Cross-Sectional Survey of Knowledge, Confidence, and Decision-Making in Acute Stroke in the Era of Anti-Amyloid Therapies

    ✓ Peer-reviewed alzhub usefulness score 53 out of 100. Journal of the American College of Clinical Pharmacy : JACCP 2026-10-01 Treatments

    EM providers and pharmacists demonstrated substantial gaps in preparedness for patients receiving AATs, including limited knowledge, low confidence, minimal clinical experience, and inadequate institutional support.

  4. Alzheimer's disease in the Plasticene era: a clinicopathological update on the dual sequestration of amyloid and tau as hijacked innate immune responses

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Free neuropathology 2026-06-22 Treatments

    We suggest that Aβ plaques and tau NFTs could be reinterpreted as evolutionarily conserved, compartment-specific innate immune sequestration mechanisms-an extracellular "sarcophagus" and an intracellular "lockbox"-based on their roles in microbial defense and stress response.

  5. White matter hyperintensities in Alzheimer's disease in the era of anti-amyloid therapies

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2026-04-01 Treatments

    White matter hyperintensities (WMHs) are highly prevalent in Alzheimer's disease (AD) and arise from interacting vascular pathologies (including hypertensive small vessel disease and cerebral amyloid angiopathy) alongside inflammatory and neurodegenerative processes.

  6. One Hundred Cerebral Microhemorrhages: Rethinking Cerebral Amyloid Angiopathy in the Era of Amyloid-Targeted Antibodies

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Cureus 2026-03-12 Treatments

    We report a case of probable cerebral amyloid angiopathy (CAA) presenting with almost 100 cerebral microhemorrhages in an apolipoprotein E 4 (APOE4) homozygous subject with mild cognitive impairment (MCI).

  7. Anti-Amyloid Imaging Abnormality in the Era of Anti-Amyloid Beta Monoclonal Antibodies: Recent Updates for the Radiologist

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of the Korean Society of Radiology 2025-01-24 Treatments

    Lecanemab and donanemab have received full U.S. Food and Drug Administration (FDA) approval, and subsequently, lecanemab has been approved by the Korean FDA and it has recently entered commercial use in Korea.

  8. HIV-1 infection and cognitive impairment in the cART era: a review

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. AIDS (London, England) 2011-03-01 Tau biomarkers

    With the introduction of combination antiretroviral therapy AIDS dementia complex or HIV-associated dementia, as it was termed later, largely disappeared in clinical practice.

  9. Genetics of Alzheimer disease in the pre- and post-GWAS era

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer's research & therapy 2010-03-05 Genetics

    Since the 1990s, the genetics of Alzheimer disease (AD) has been an active area of research.

All topic tags with their study counts